Capstan Therapeutics


capstan health logo

Vision

We transform medicine by in vivo precision engineering of cells.

Approach

Capstan Therapeutics is advancing precision in vivo engineering in a scalable and controlled format to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to deliver breakthrough medicines to patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders.

CEO:

Laura Shawver, Ph.D., - President and CEO

Founding CEO:

Christian Homsy, M.D., MBA

First investment:

June 2022